Exceeded Adjusted EBITDA Expectations
Evolent reported adjusted EBITDA of $37.5 million, which was in the top half of their range, driven by strong results across both Technology and Services and Performance Suite models.
New Revenue Agreements
Four new revenue agreements across Technology and Services and the Performance Suite were announced, bringing the total to 11 new agreements year-to-date, with expected total new revenue in excess of $250 million by Q1 2026.
Aetna Partnership
Announced a partnership with Aetna for oncology services across 250,000 Medicare Advantage members in Florida, with plans to launch in Q1 2026 and potential for expansion to additional states.
AI and Automation Initiatives
Progress in AI and automation work has improved review efficiency by 11% in the last quarter. The goal is to become an AI-first company, targeting 80% of current authorization volume to be auto-approved.
Strong Pipeline
A weighted pipeline of $1 billion in new business was reported, indicating strong future revenue potential.